Compare with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SUVEN LIFESCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SUVEN LIFESCIENCES ALKEM LABORATORIES/
SUVEN LIFESCIENCES
 
P/E (TTM) x - 19.4 - View Chart
P/BV x 6.6 3.9 168.7% View Chart
Dividend Yield % 0.7 0.5 121.8%  

Financials

 ALKEM LABORATORIES   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SUVEN LIFESCIENCES
Mar-19
ALKEM LABORATORIES/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs1,589338 470.5%   
Low Rs1,232169 727.3%   
Sales per share (Unadj.) Rs417.552.1 800.8%  
Earnings per share (Unadj.) Rs56.36.8 824.1%  
Cash flow per share (Unadj.) Rs64.78.6 755.0%  
Dividends per share (Unadj.) Rs12.701.50 846.7%  
Dividend yield (eoy) %0.90.6 152.2%  
Book value per share (Unadj.) Rs292.965.3 448.7%  
Shares outstanding (eoy) m119.57127.28 93.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.9 69.5%   
Avg P/E ratio x25.137.1 67.5%  
P/CF ratio (eoy) x21.829.6 73.7%  
Price / Book Value ratio x4.83.9 124.0%  
Dividend payout %22.622.0 102.7%   
Avg Mkt Cap Rs m168,65332,272 522.6%   
No. of employees `000NA1.1 0.0%   
Total wages/salary Rs m9,171661 1,387.1%   
Avg. sales/employee Rs ThNM6,132.2-  
Avg. wages/employee Rs ThNM611.1-  
Avg. net profit/employee Rs ThNM803.5-  
INCOME DATA
Net Sales Rs m49,9156,635 752.3%  
Other income Rs m1,645242 679.0%   
Total revenues Rs m51,5616,877 749.7%   
Gross profit Rs m8,4821,604 528.8%  
Depreciation Rs m1,006221 454.3%   
Interest Rs m67138 1,778.8%   
Profit before tax Rs m8,4511,587 532.4%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606718 223.7%   
Profit after tax Rs m6,731869 774.2%  
Gross profit margin %17.024.2 70.3%  
Effective tax rate %19.045.2 42.0%   
Net profit margin %13.513.1 102.9%  
BALANCE SHEET DATA
Current assets Rs m27,0626,232 434.2%   
Current liabilities Rs m15,3241,490 1,028.4%   
Net working cap to sales %23.571.5 32.9%  
Current ratio x1.84.2 42.2%  
Inventory Days Days6786 76.9%  
Debtors Days Days4183 50.0%  
Net fixed assets Rs m12,6104,043 311.9%   
Share capital Rs m239127 187.8%   
"Free" reserves Rs m34,4908,183 421.5%   
Net worth Rs m35,0278,310 421.5%   
Long term debt Rs m1,21218 6,806.7%   
Total assets Rs m54,38710,389 523.5%  
Interest coverage x13.643.1 31.6%   
Debt to equity ratio x00 1,614.9%  
Sales to assets ratio x0.90.6 143.7%   
Return on assets %13.68.7 155.9%  
Return on equity %19.210.5 183.7%  
Return on capital %24.919.5 127.4%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,5635,622 116.7%   
Fx outflow Rs m3,0121,799 167.4%   
Net fx Rs m3,5523,822 92.9%   
CASH FLOW
From Operations Rs m7,259356 2,041.8%  
From Investments Rs m1,864-279 -669.1%  
From Financial Activity Rs m-9,273-225 4,119.4%  
Net Cashflow Rs m-150-148 101.2%  

Share Holding

Indian Promoters % 66.9 63.4 105.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 36.5 -  
Shareholders   68,381 37,287 183.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  AJANTA PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 20, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS